Table 1:
Demographic and clinical characteristicsa
| Controls n = 15 | PSP n = 24 | CBD n = 9 | MSA n = 19 | PD n = 18 | P Value | |
|---|---|---|---|---|---|---|
| Demographic data | ||||||
| Sex (M/F) | 8:7 | 13:11 | 4:5 | 14:5 | 10:8 | .454b |
| Age (yr) | 62.6 (9.0) | 63.2 (6.8) | 67.9 (5.6) | 64.2 (7.1) | 64.4 (9.3) | .433c |
| Disease duration (yr) | NA | 3.3 (1.8) | 3.3 (1.8) | 3.1 (2.1) | 10.6 (6.1) | <.001c |
| Clinical data | ||||||
| UPDRS III | NA | 21.3 (9.8) | 25.2 (7.1) | 19.6 (19.1) | 32.3 (11.5) | .875c |
| UPDRSbrad | NA | 6.1 (4.7) | 12.5 (3.6) | 7.7 (9.3) | 14.5 (8.4) | .134c |
| UPDRSrig | NA | 4.1 (3.0) | 7.2 (4.4) | 3.9 (5.6) | 9.2 (6.5) | .266c |
| White matter lesion burden assessment | ||||||
| Fazekas PVH score | 0.38 (0.65) | 0.71 (0.75) | 0.70 (0.48) | 0.37 (0.50) | 0.47 (0.62) | .321c |
| Fazekas DWMH score | 0.77 (0.73) | 0.54 (0.66) | 0.40 (0.52) | 0.53 (061) | 0.53 (0.51) | .684c |
Note:—DWMH indicates deep white matter hyperintensity; UPDRS, Unified Parkinson Disease Rating Scale; UPDRSbrad, bradykinesia subscore of UPDRS; UPDRSrig, rigidity subscore of UPDRS; PVH, periventricular; NA, not applicable.
a
Data are presented as mean (SD).
b
χ2 test.
c
ANOVA.